MAPT and Alzheimer disease: So, A status is determined using fluid assays (cerebrospinal fluid (CSF) or plasma), in which Aβ proteinopathy or phosphorylated/secreted AD tau (T1) is measured, or amyloid PET (positron emission tomography).